The Phase 2 AscenSION CF trial initiation in Q1 2027 is the key near-term catalyst. Monitor enrollment and any early efficacy signals (sweat chloride reduction) from the 28-day study. The cash runway into H2 2029 reduces near-term dilution risk.
Drugs in focus
SION drug pipeline →SION-2222
● Neutral Named in this press release- Impact
- Phase
- Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
- Time to market
- At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
- Next catalyst
- None dated
What to watchThe next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Nov 10 $3.70entry
- T+1 · 6d ago 0.00%α −1.32% · $3.70
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sionna reported a Q3 2026 net loss of $32.4M ($0.72 per share), wider than the $20.3M loss a year ago, and ended the quarter with $249.8M in cash. The company announced a 46% workforce reduction and plans to initiate a Phase 2 proof-of-concept trial for its lead dual combination SION-451 + SION-2222 in Q1 2027, after the SION-719 add-on trial failed to meet its endpoint.
Key Financial Metrics
Key Facts
- Net loss of $32.4M for Q3 2026, compared to $20.3M in Q3 2025
- Net loss per share of $0.72, compared to $0.46 in the year-ago quarter
- Cash, cash equivalents and marketable securities of $249.8M as of September 30, 2026
- Workforce reduction of approximately 46% implemented in September 2026
- SION-451 + SION-2222 dual combination advancing to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027
- PreciSION CF Phase 2a trial of SION-719 did not achieve its key activity endpoint; SION-719 not advancing as add-on to standard of care
- Cash runway expected to fund operations into the second half of 2029
Financial Impact
Net loss widened by $12.1M YoY; cash burn of $60.5M in the nine months ended September 30, 2026; workforce reduction expected to reduce operating expenses
Risk Factors
- SION-451 + SION-2222 is still in early-stage development; Phase 2 results may not replicate preclinical or Phase 1 data
- Failure of SION-719 as add-on to Trikafta raises questions about NBD1 stabilization approach in combination with existing therapies
- Workforce reduction may impact morale and ability to execute on pipeline
- Competition from Vertex's Trikafta and other CFTR modulators
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399301 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Viewing Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers